Imagine a camera that doesn't just take a picture, but instantly identifies the chemical 'fingerprint' of a cell. It uses special laser fibers and AI to spot diseased cells in real-time, almost like a high-speed video. This helps doctors find the exact boundaries of a tumor during surgery without waiting for slow lab tests.
Current live cell imaging is too slow and limited in scope to fully understand biochemical disruptions. This gap prevents the development of personalized medical treatments and leads to high healthcare costs and loss of life.
A multimodal photonics platform combining non-linear optical fibers, wide-band coherent Raman, and AI to image biological tissues at video rates.
If you are an equipment manufacturer dealing with slow biopsy turnaround times — this project developed a multimodal photonics platform that enables real-time imaging during cystoscopy. This allows for more precise resection of bladder cancer directly in the operating room.
If you are a lab dealing with the slow pace of observing how cells react to new drugs — this project developed a laser platform that images at video rates. This speeds up the discovery of new biomarkers and the understanding of cellular disruptions.
If you are a diagnostics company dealing with low-resolution chemical analysis in lab-on-a-chip devices — this project developed coherent Raman light sources suitable for microfluidic channels. This increases the accuracy and speed of biochemical cellular makeup analysis.
Based on available project data, specific pricing or cost figures for the final platform are not provided.
Yes, the project aims for TRL 6, which focuses on creating a sustainable supply chain to ensure a first-mover advantage in the market.
Based on available project data, specific licensing terms are not listed, but the consortium includes 4 industry partners and 5 SMEs likely involved in commercialization.
The project is scheduled to end on June 30, 2027, targeting a technology readiness level of TRL 6 by that time.
The platform is designed to be versatile and practical, specifically targeting integration into medical imaging instruments such as endoscopes for bladder cancer resection.
The consortium is strongly geared toward commercialization, featuring a 33% industry ratio with 4 industrial partners and 5 SMEs. With 12 partners across 6 countries (BE, CZ, DE, FR, IE, TR), the project balances academic research (3 universities, 5 research centers) with practical market application, ensuring the transition from lab to TRL 6.
University of Limerick
Contact us to connect with the uCAIR consortium for TRL 6 licensing opportunities.
